The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Featured:
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub was pleased to speak to Bhagirathbhai Dholaria, Vanderbilt University Medical Center, Nashville, US. We asked, What is the role of transplant in CNL? What are the key considerations about timing of transplant in CNL?
What is the role of transplant in CNL? Key considerations about timing of transplant in CNL
Dholaria begins by discussing the difficulties in obtaining data on the effectiveness of allogeneic transplants in patients with CNL. Dholaria goes on to speak about a large-scale observational study, combining data from the CIBMTR and European transplant registry, and gives an insight into disease-free and overall survival in CNL. Finally, Dholaria touches on the role of pre-transplant therapies, such as ruxolitinib, in improving patient outcomes.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?